Kevin Sharp, Executive Vice President and Head of Sales & Operations at Samsung Biologics, shared insights on Samsung’s new Organoids platform, which enables clients to better model patient response in the R&D of novel molecules, and highlights the company’s newly opened ADC facility, providing full antibody development, manufacturing, and conjugation services, with expansion into ADC drug product development on the horizon.
